These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10648391)

  • 1. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse.
    Tobal K; Newton J; Macheta M; Chang J; Morgenstern G; Evans PA; Morgan G; Lucas GS; Liu Yin JA
    Blood; 2000 Feb; 95(3):815-9. PubMed ID: 10648391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
    Tobal K; Yin JA
    Blood; 1996 Nov; 88(10):3704-9. PubMed ID: 8916934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
    Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
    Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia.
    Kondo M; Kudo K; Kimura H; Inaba J; Kato K; Kojima S; Matsuyama T; Horibe K
    Leuk Res; 2000 Nov; 24(11):951-6. PubMed ID: 11086178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.
    Marcucci G; Livak KJ; Bi W; Strout MP; Bloomfield CD; Caligiuri MA
    Leukemia; 1998 Sep; 12(9):1482-9. PubMed ID: 9737700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients.
    Krauter J; Wattjes MP; Nagel S; Heidenreich O; Krug U; Kafert S; Bunjes D; Bergmann L; Ganser A; Heil G
    Br J Haematol; 1999 Oct; 107(1):80-5. PubMed ID: 10520027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of minimal residual disease in t(8;21)-positive acute myelogenous leukemia patients using real-time quantitative RT-PCR.
    Sugimoto T; Das H; Imoto S; Murayama T; Gomyo H; Chakraborty S; Taniguchi R; Isobe T; Nakagawa T; Nishimura R; Koizumi T
    Am J Hematol; 2000 Jun; 64(2):101-6. PubMed ID: 10814988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A quantitative reverse transcriptase polymerase chain reaction method for the detection of leukaemic cells with t(8;21) in peripheral blood.
    Fujimaki S; Funato T; Harigae H; Imaizumi M; Suzuki H; Kaneko Y; Miura Y; Sasaki T
    Eur J Haematol; 2000 Apr; 64(4):252-8. PubMed ID: 10776697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disappearance of AML1-MTG8 transcript by reverse transcriptase polymerase chain reaction in a patient in remission of acute myeloid leukemia (M2) after low-dose cytosine arabinoside.
    Sawada H; Serino Y; Wake A; Yamasaki Y; Izumi Y
    Leuk Res; 1998 Sep; 22(9):853-7. PubMed ID: 9716019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia.
    Qin YZ; Wang Y; Xu LP; Zhang XH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Chen Y; Mo XD; Zhao XS; Chang YJ; Liu KY; Huang XJ
    J Hematol Oncol; 2017 Feb; 10(1):44. PubMed ID: 28166825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
    Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
    Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia.
    Jurlander J; Caligiuri MA; Ruutu T; Baer MR; Strout MP; Oberkircher AR; Hoffmann L; Ball ED; Frei-Lahr DA; Christiansen NP; Block AM; Knuutila S; Herzig GP; Bloomfield CD
    Blood; 1996 Sep; 88(6):2183-91. PubMed ID: 8822938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the polymerase chain reaction in the detection of AML1/ETO fusion transcript in t(8;21).
    Kwong YL; Chan V; Wong KF; Chan TK
    Cancer; 1995 Feb; 75(3):821-5. PubMed ID: 7828132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
    Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
    Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
    Kusec R; Laczika K; Knöbl P; Friedl J; Greinix H; Kahls P; Linkesch W; Schwarzinger I; Mitterbauer G; Purtscher B
    Leukemia; 1994 May; 8(5):735-9. PubMed ID: 7514242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia.
    Wattjes MP; Krauter J; Nagel S; Heidenreich O; Ganser A; Heil G
    Leukemia; 2000 Feb; 14(2):329-35. PubMed ID: 10673753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
    Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
    Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia.
    Zhang L; Cao Z; Ruan M; Zeng Q; Zhao L; Li Q; Zou Y; Wang J; Zhu X
    Pediatr Blood Cancer; 2014 Oct; 61(10):1761-6. PubMed ID: 24920269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.